Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

CAR-T design: Elements and their synergistic function
Jayapriya Jayaraman, Michael Mellody, Andrew J. Hou, et al.
EBioMedicine (2020) Vol. 58, pp. 102931-102931
Open Access | Times Cited: 230

Showing 1-25 of 230 citing articles:

Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study
Jeremy S. Abramson, M. Lia Palomba, Leo I. Gordon, et al.
The Lancet (2020) Vol. 396, Iss. 10254, pp. 839-852
Closed Access | Times Cited: 1716
T cells in health and disease
Lina Sun, Yanhong Su, Anjun Jiao, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 286
Management of Immunotherapy-Related Toxicities, Version 1.2022, NCCN Clinical Practice Guidelines in Oncology
John A. Thompson, Bryan J. Schneider, Julie R. Brahmer, et al.
Journal of the National Comprehensive Cancer Network (2022) Vol. 20, Iss. 4, pp. 387-405
Open Access | Times Cited: 285
Gene therapy clinical trials, where do we go? An overview
Fatemeh Arabi, Vahid Mansouri, Naser Ahmadbeigi
Biomedicine & Pharmacotherapy (2022) Vol. 153, pp. 113324-113324
Open Access | Times Cited: 152
CAR-NK cells for cancer immunotherapy: from bench to bedside
Leisheng Zhang, Meng Yuan, Xiaoming Feng, et al.
Biomarker Research (2022) Vol. 10, Iss. 1
Open Access | Times Cited: 124
Cell therapies in the clinic
Liwen Wang, Morgan E. Janes, Ninad Kumbhojkar, et al.
Bioengineering & Translational Medicine (2021) Vol. 6, Iss. 2
Open Access | Times Cited: 104
CAR-NK Cells in the Treatment of Solid Tumors
Ewa Wrona, Maciej Borowiec, Piotr Potemski
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 11, pp. 5899-5899
Open Access | Times Cited: 104
Use of CAR T-cell for acute lymphoblastic leukemia (ALL) treatment: a review study
Mohsen Sheykhhasan, Hamed Manoochehri, Paola Dama
Cancer Gene Therapy (2022) Vol. 29, Iss. 8-9, pp. 1080-1096
Open Access | Times Cited: 99
Nanobody-based CAR-T cells for cancer immunotherapy
Pouya Safarzadeh Kozani, Abdolhossein Naseri, Seyed Mohamad Javad Mirarefin, et al.
Biomarker Research (2022) Vol. 10, Iss. 1
Open Access | Times Cited: 96
Current updates on generations, approvals, and clinical trials of CAR T-cell therapy
Tadesse Asmamaw Dejenie, Markeshaw Tiruneh G Medhin, Gashaw Dessie Terefe, et al.
Human Vaccines & Immunotherapeutics (2022) Vol. 18, Iss. 6
Open Access | Times Cited: 81
CAR-T Regulatory (CAR-Treg) Cells: Engineering and Applications
Motahareh Arjomandnejad, Acadia L. Kopec, Allison M. Keeler
Biomedicines (2022) Vol. 10, Iss. 2, pp. 287-287
Open Access | Times Cited: 66
Chimeric Antigen Receptor T-Cells: An Overview of Concepts, Applications, Limitations, and Proposed Solutions
Alaa Alnefaie, Sarah Albogami, Yousif A. Asiri, et al.
Frontiers in Bioengineering and Biotechnology (2022) Vol. 10
Open Access | Times Cited: 66
CAR T Cell Therapy: A Versatile Living Drug
Rodrigo C. De Marco, Héctor J. Monzó, Päivi M. Ojala
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 7, pp. 6300-6300
Open Access | Times Cited: 57
Current and future concepts for the generation and application of genetically engineered CAR-T and TCR-T cells
Michael Hiltensperger, Angela M. Krackhardt
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 38
Programmable synthetic receptors: the next-generation of cell and gene therapies
Fei Teng, Tongtong Cui, Li Zhou, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 16
B cell-targeting chimeric antigen receptor T cells as an emerging therapy in neuroimmunological diseases
Aiden Haghikia, Georg Schett, Dimitrios Mougiakakos
The Lancet Neurology (2024) Vol. 23, Iss. 6, pp. 615-624
Open Access | Times Cited: 15
Targeting the tumor microenvironment in B-cell lymphoma: challenges and opportunities
Yingyue Liu, Xiangxiang Zhou, Xin Wang
Journal of Hematology & Oncology (2021) Vol. 14, Iss. 1
Open Access | Times Cited: 80
Improving CAR T-Cell Persistence
Violena Pietrobon, Lauren A. Todd, Anghsumala Goswami, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 19, pp. 10828-10828
Open Access | Times Cited: 69
The Application of Nanobody in CAR-T Therapy
Chaolemeng Bao, Quanli Gao, Linlin Li, et al.
Biomolecules (2021) Vol. 11, Iss. 2, pp. 238-238
Open Access | Times Cited: 66
In-Vivo Induced CAR-T Cell for the Potential Breakthrough to Overcome the Barriers of Current CAR-T Cell Therapy
Tianqing Xin, Cheng Li, Chuchao Zhou, et al.
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 55
Immunogenicity of CAR-T Cell Therapeutics: Evidence, Mechanism and Mitigation
Aalia Khan, Ambalika Chowdhury, Atharva Karulkar, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 55
CAR density influences antitumoral efficacy of BCMA CAR T cells and correlates with clinical outcome
Paula Rodríguez-Márquez, María Eréndira Calleja-Cervantes, Guillermo Serrano, et al.
Science Advances (2022) Vol. 8, Iss. 39
Open Access | Times Cited: 47
Strategies to enhance CAR-T persistence
Yue Liu, Lingna An, Ruihao Huang, et al.
Biomarker Research (2022) Vol. 10, Iss. 1
Open Access | Times Cited: 47
Ciltacabtagene autoleucel: The second anti-BCMA CAR T-cell therapeutic armamentarium of relapsed or refractory multiple myeloma
Endeshaw Chekol Abebe, Mestet Yibeltal Shiferaw, Fitalew Tadele Admasu, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 43
The affinity of antigen-binding domain on the antitumor efficacy of CAR T cells: Moderate is better
Rui Mao, Wanqing Kong, Yukai He
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 41
Page 1 - Next Page

Scroll to top